Resonance Health Limited (ASX: RHT) is pleased to announce the appointment of Mr Michael Sistenich and Dr David Fuller as Non-Executive Directors, enhancing the Board's expertise in capital markets, healthcare technology, clinical development, and global commercialisation. Mr Sistenich brings deep experience in healthcare AI, medtech, and investment banking, while Dr Fuller offers expertise in drug development, clinical research, and regulatory strategy.

These appointments signify our commitment to Board renewal and strategic growth. Mr Aaron Brinkworth, Resonance Health Chairperson, highlighted the valuable skills and experience these new Directors bring as we expand globally and advance our technology and product portfolio.

For more information, visit our website. Feel free to reach out to Andrew Harrison, Managing Director, for any inquiries at andrewh@resonancehealth.com or +61 8 9286 5300.

Resonance Health is a leading Australian healthcare technology company known for its high-quality quantitative assessments in disease management and drug development. Our regulatory cleared SaMDs, including products like FerriScan® and HepaFatScan®, have gained global recognition and endorsement from physicians. We continue to develop innovative medical imaging analysis products and offer clinical trial management services to support our mission in advancing healthcare technology.

Join us on our journey by visiting our website and following us on LinkedIn. Your feedback and engagement are important to us.